News | Mobile Devices | June 13, 2018

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

Use of medication management mobile app increased prescription refill rates by almost 10 percent

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients increase their prescription refills by almost 10 percent after they start using the company's mobile app.

In order to determine the increase in prescription claims, the study matched Medisafe users to their refill data using a HIPAA-compliant, non-identification process. The investigators calculated a medication possession ratio ("MPR") for each of the over 4,000 patients taking an antihypertensive medication pre-app (before the patient started using Medisafe) and on-app (once the patient started using Medisafe) and grouped them into corresponding MPR deciles (0 - 0.1 being the least adherent, 0.9 - 1.0 being the most adherent). MPR is a standard metric used by the healthcare industry to track medication adherence, in which an MPR of 1.0 corresponds to a 100 percent refill rate.  

Key findings include:

  • Of patients not in the top MPR decile pre-app, 82 percent (1,371 of 1,667) increased by at least one decile on-app;
  • Of patients with a pre-app MPR < 0.8, 78 percent (920 of 1,179) increased by at least 2 deciles;
  • Of patients with a pre-app MPR < 0.5, 74 percent of patients (320 of 431) increased by at least 5 deciles; and
  • The proportion of patients with MPR ≥ 0.80 increased from 70.8 percent pre-app to 86.25 percent on-app, a 21.8 percent relative increase.

 

Summary Table

Adherence (MPR) Pre-app On-app p-value % change
Mean 0.84 0.92 <.0001 9.52%
Standard deviation 0.23 0.13    
Adherent [MPR ≥ 0.80] 2858 (71%) 3482 (86%) <.0001 21.13%

N= 4,037

 

The hypertension results follow data released from the same landmark study in early March on the accuracy of Medisafe's patient reported adherence data. In the coming months, Medisafe will continue to release results, including data regarding the platform's impact on adherence and persistence across other therapeutic areas.

For more information: www.medisafe.com


Related Content

News | Cardiovascular Clinical Studies

January 26, 2023 — A newly-released study extends the understanding of how acquired mutations in blood cells act as a ...

Home January 26, 2023
Home
News | Cardiovascular Clinical Studies

January 24, 2023 — Four cardiology organizations have joined forces in a call to action to reinvent randomized clinical ...

Home January 24, 2023
Home
News | Cardiovascular Clinical Studies

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

Home January 11, 2023
Home
News | Cardiovascular Clinical Studies

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home January 03, 2023
Home
News | Cardiovascular Clinical Studies

December 30, 2022 — The Cardiovascular Research Foundation (CRF) recently announced that Alexandra Popma, MD, has joined ...

Home December 30, 2022
Home
News | Cardiovascular Clinical Studies

December 28 2022 — Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of ...

Home December 28, 2022
Home
News | Cardiovascular Clinical Studies

December 27, 2022 — A groundbreaking new clinical trial to determine the effectiveness of a new treatment for patients ...

Home December 27, 2022
Home
News | Cardiovascular Clinical Studies

December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home December 21, 2022
Home
News | Cardiovascular Clinical Studies

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
Home
News | Cardiovascular Clinical Studies

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

Home December 09, 2022
Home
Subscribe Now